Skip to main content
MedPathMedPath Home
Clinical Trials/TCTR20200313005
TCTR20200313005
Enrolling By Invitation
未知

Effectiveness and safety of direct acting antivirals for the management of patients with chronic hepatitis C virus in Thailand : A real-life multicenter study.

one0 sites200 target enrollmentMarch 13, 2020
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions1.End of treatment response (ETR) is the rate of treatment response. At the temple at the time of study discontinuance Which is divided into biochemical responses (with liver enzymes&#44ALT) and virologDAA.Chornic hepatitis C.

Overview

Phase
未知
Intervention
Not specified
Conditions
1.End of treatment response (ETR) is the rate of treatment response. At the temple at the time of study discontinuance Which is divided into biochemical responses (with liver enzymes&#44
Sponsor
one
Enrollment
200
Status
Enrolling By Invitation
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 13, 2020
End Date
August 29, 2017
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
one

Eligibility Criteria

Inclusion Criteria

  • •1\. Patients aged 18 years and older who are admitted to institutions participating in the chronic hepatitis C research project during the year 2015\-present
  • •2\. Patients are treated with Direct Acting Antivirals and may or may not be combined with ribavirin.

Exclusion Criteria

  • •1\. Patients younger than 18 years of age
  • •2\. Pregnant patients.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Assessment of indication and efficacy of anti-viral therapy based on mucosal PCR assay in active UC patients with CMV infection.lcerative colitis
JPRN-UMIN000022588Department of Gastroenterology and Hepatology, Kyoto University Hospital120
Completed
Not Applicable
Analysis of efficacy and safety of antiviral therapy with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantatiohepatitis C after liver transplantation
JPRN-UMIN000014583Kyoto University Hospital30
Completed
Not Applicable
Analysis of efficacy and safety of antiviral therapy with daclatasvir and asunaprevir for hepatitis C after organ transplantation -Pilot Studyhepatitis C after transplantation
JPRN-UMIN000016558Trasnplantation surgery, Hiroshima University Hospital20
Recruiting
Not Applicable
Analysis of efficacy and safety of antiviral therapy with telaprevir, peginterferon and ribavirin for recurrent hepatitis C after liver transplantatiohepatitis C after liver transplantation
JPRN-UMIN000009171Kyoto University Hospital20
Recruiting
Not Applicable
Analysis of efficacy and safety of antiviral therapy with simeprevir, peginterferon and ribavirin for recurrent hepatitis C after liver transplantatiohepatitis C after liver transplantation
JPRN-UMIN000012219Kyoto University Hospital30